Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Issues raised by GUSTO

H White1

  • 1Green Lane Hospital, Auckland, New Zealand.

Australian and New Zealand Journal of Medicine
|December 1, 1993
PubMed
Summary
This summary is machine-generated.

The GUSTO trial questioned heparin

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The gut microbiota in adults with cystic fibrosis compared to colorectal cancer.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2023
Same author

Estimation of genetic parameters for feed efficiency traits using random regression models in dairy cattle.

Journal of dairy science·2023
Same author

Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2023
Same author

Can ultrasound strain elastography (USE) improve management of suspicious thyroid nodules measuring <10 mm? A systematic review.

Radiography (London, England : 1995)·2023
Same author

Diabetes is associated with increased burden of gastrointestinal symptoms in adults with cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2023
Same author

Cystic Fibrosis-Related Gut Dysbiosis: A Systematic Review.

Digestive diseases and sciences·2023
Same journal

Gastroenterological Society of Australia, Annual Scientific Meeting, May 1980.

Australian and New Zealand journal of medicine·2020
Same journal

'A touch of sugar'--a dangerous euphemism still alive and well.

Australian and New Zealand journal of medicine·2001
Same journal

Silent myocardial ischaemia following methysergide overdose.

Australian and New Zealand journal of medicine·2001
Same journal

Extensive jugular and upper limb thrombosis in a patient with factor V Leiden mutation and non-Hodgkin's lymphoma.

Australian and New Zealand journal of medicine·2001
Same journal

Visual loss as the presenting feature of giant cell arteritis.

Australian and New Zealand journal of medicine·2001
Same journal

Lymphoproliferative disease causing angioedema--an uncommon association.

Australian and New Zealand journal of medicine·2001
See all related articles

Area of Science:

  • Cardiology and Thrombosis Research

Background:

  • The GUSTO trial investigated thrombolytic therapy for myocardial infarction.
  • The optimal use of heparin in conjunction with thrombolytics remains unclear.

Purpose of the Study:

  • To evaluate the role of heparin administration (intravenous vs. subcutaneous) with streptokinase (SK) in thrombolysis.
  • To determine if tissue plasminogen activator (t-PA) superiority was due to administration timing or heparin.

Main Methods:

  • Analysis of data from the GUSTO trial, focusing on patient subgroups and treatment protocols.
  • Comparison of outcomes between different thrombolytic agents and heparin regimens.

Main Results:

  • The GUSTO trial did not clarify the optimal heparin regimen for streptokinase therapy.

Related Experiment Videos

  • Tissue plasminogen activator (t-PA) may have shown superiority due to faster administration, not necessarily the associated heparin.
  • While survival improved, optimal reperfusion rates remain a challenge.

    • Conclusions:

    • Further research is needed to define the precise role and optimal administration of heparin in thrombolytic therapy.
    • Accelerated administration of thrombolytics is a critical factor in improving outcomes.
    • Enhancing reperfusion rates remains a key goal in acute myocardial infarction treatment.